Advertisement
Advertisement

VRCA

VRCA logo

Verrica Pharmaceuticals Inc. Common Stock

6.92
USD
Sponsored
+0.31
+4.69%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

6.86

-0.06
-0.94%

VRCA Earnings Reports

Positive Surprise Ratio

VRCA beat 16 of 30 last estimates.

53%

Next Report

Date of Next Report
Feb 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
$4.62M
/
-$0.81
Implied change from Q3 25 (Revenue/ EPS)
-67.82%
/
+2600.00%
Implied change from Q4 24 (Revenue/ EPS)
+1241.72%
/
-66.25%

Verrica Pharmaceuticals Inc. Common Stock earnings per share and revenue

On Nov 14, 2025, VRCA reported earnings of -0.03 USD per share (EPS) for Q3 25, beating the estimate of -0.68 USD, resulting in a 95.64% surprise. Revenue reached 14.34 million, compared to an expected 5.96 million, with a 140.70% difference. The market reacted with a -5.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.81 USD, with revenue projected to reach 4.62 million USD, implying an increase of 2600.00% EPS, and decrease of -67.82% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Verrica Pharmaceuticals Inc. Common Stock reported EPS of -$0.03, beating estimates by 95.64%, and revenue of $14.34M, 140.7% above expectations.
The stock price moved down -5.09%, changed from $3.93 before the earnings release to $3.73 the day after.
The next earning report is scheduled for Feb 26, 2026.
Based on 7 analysts, Verrica Pharmaceuticals Inc. Common Stock is expected to report EPS of -$0.81 and revenue of $4.62M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement